FDA should be able to establish a priority review process for generic drugs where there is minimal price competition for an off-patent drug, Gerard Anderson, professor of health policy and management at Johns Hopkins University, told the Senate Special Committee on Aging at a Dec. 9 hearing.
Such an approach would help to deter drug firms like Turing Pharmaceuticals AG and Valeant Pharmaceuticals International Inc....